Literature DB >> 9375824

Kidney and breast cysts: a comparative study of fluids.

D K Hurley1, S M Bandy, R H Glew, D M Morris, K D Gardner.   

Abstract

The contributions of amino acids to the overall osmotic activity of cyst fluids were sought in this comparative study of fluids from the cysts of autosomal dominant polycystic disease (ADPKD) and gross cystic disease of the breast (GCDB). Fluids (n = 18) from 18 women with GCDB and from 8 patients with ADPKD (n = 25), grouped on the basis of sodium concentrations, were analyzed for potassium, chloride, protein, and osmolality by routine methods and for amino acids by reversed-phase high-pressure liquid chromatography. Similarities between kidney and breast cyst fluids included relative isosmolality, a wide range of sodium concentrations, an inverse relationship between sodium and potassium concentrations, higher concentrations of amino acids in low-sodium fluids, and significant correlations between sequential concentrations of amino acids in cyst fluids versus blood and some of its components. Therefore, cyst fluids in ADPKD and GCDB share compositional characteristics, and amino acids, possibly of blood protein origin, accumulate in small but osmotically significant amounts in some, particularly low-sodium, cysts of kidney and breast.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9375824     DOI: 10.1159/000190292

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  2 in total

1.  Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease.

Authors:  Ramón Peces; Emilio Cuesta-López; Carlos Peces; Virginia Pérez-Dueñas; Cristina Vega-Cabrera; Rafael Selgas
Journal:  Int Urol Nephrol       Date:  2010-05-07       Impact factor: 2.370

2.  Purinergic signaling in the lumen of a normal nephron and in remodeled PKD encapsulated cysts.

Authors:  Michael B Hovater; Dragos Olteanu; Elisabeth A Welty; Erik M Schwiebert
Journal:  Purinergic Signal       Date:  2008-04-26       Impact factor: 3.765

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.